Skip to content
PubMed This is a summary of 7 peer-reviewed journal articles Updated
Neurology · Juvenile-onset Parkinson disease 19A

Getting a Definitive Diagnosis for PARK19A

At a Glance

PARK19A is generally confirmed when a child has a compatible clinical picture and pathogenic or likely pathogenic variants in both copies of the DNAJC6 gene. Genetic panels or exome sequencing are central; DaTscans and spinal taps are not routinely required.

Confirming a diagnosis of PARK19A (also known as DNAJC6-related parkinsonism) is a multi-step process that relies on genetic testing. Because the symptoms can overlap with other rare movement disorders or childhood-onset conditions, doctors use specific tests to rule out other possibilities and find the exact genetic cause [1][2].

The Gold Standard: Genetic Testing

A molecular diagnosis generally requires a compatible clinical picture plus biallelic pathogenic or likely pathogenic DNAJC6 variants. Because PARK19A is autosomal recessive, a child must have a mutation in both copies of the gene [3].

Doctors typically use one of two main genetic testing methods:

  • Targeted Gene Panels: A “juvenile parkinsonism” or “early-onset movement disorder” panel tests a pre-selected group of genes known to cause similar symptoms [2].
  • Whole Exome Sequencing (WES): If a panel doesn’t find the answer, WES looks at all the protein-coding regions of a child’s DNA. Exome or genome testing may also be used first-line in a child with developmental or multisystem disease [4][2].

Supporting Evidence: Imaging and CSF

While genetic testing provides the “name” of the condition, other tests have been used in research or to rule out other diseases [1].

  • DaTscan (SPECT Imaging): In a small number of children with the severe juvenile form of PARK19A, these scans showed reduced or absent tracer uptake in the basal ganglia. However, DaTscans are not required for a molecular diagnosis [1].
  • Cerebrospinal Fluid (CSF) Analysis: A lumbar puncture is not a routine confirmation test. In small studies:
    • Reduced Homovanillic Acid (HVA): Low levels can sometimes cause PARK19A to be mistaken for a “primary neurotransmitter disorder” [1][5].
    • Increased Cyclin G-associated Kinase (GAK): This is an exploratory research finding, not a widely available or validated diagnostic test [1].

Your Genetic Laboratory Report Checklist

When you receive the genetic laboratory report, it should contain several key pieces of information to confirm a diagnosis of PARK19A [6][3]:

  • [ ] Gene Name: Must clearly list the DNAJC6 gene.
  • [ ] Genotype Status: Must state the mutations affect both copies. This may be described as homozygous or compound heterozygous [6].
  • [ ] Variant Classification: The mutations should be labeled as Pathogenic or Likely Pathogenic. A “Variant of Uncertain Significance” (VUS) cannot be used by itself to establish or rule out the diagnosis.
  • [ ] Phase/Inheritance: Parental testing is helpful to confirm the mutations are “in trans,” meaning one was inherited from each parent, especially when there are two different variants [2].
  • [ ] Mutation Detail: The report will use a code (e.g., c.1480del) to describe exactly where the gene is changed [6].

If the initial genetic test is negative but the doctor still strongly suspects PARK19A, they may order Deletion/Duplication Analysis to look for hidden changes that standard tests can miss [7][4].

Common questions in this guide

What confirms a diagnosis of PARK19A?
A diagnosis generally requires a clinical picture that fits PARK19A plus pathogenic or likely pathogenic variants in both copies of the DNAJC6 gene. These variants may be identified with a juvenile parkinsonism gene panel, whole-exome sequencing, or another appropriate genetic test.
What does a biallelic DNAJC6 result mean?
Biallelic means that disease-causing variants affect both copies of the DNAJC6 gene. A report may describe this as homozygous, or as compound heterozygous when two different variants are present.
Can a variant of uncertain significance diagnose PARK19A?
No. A variant of uncertain significance, or VUS, cannot by itself confirm or rule out PARK19A. Your genetics team may review the finding over time as more evidence becomes available.
Are a DaTscan or spinal tap required to diagnose PARK19A?
No. Genetic testing is central to confirming PARK19A, and a DaTscan or lumbar puncture is not routinely required for a molecular diagnosis. These tests may provide supporting or research information and may be used to evaluate other conditions.
What happens if the first genetic test is negative?
If a doctor still strongly suspects PARK19A, additional testing may be considered. Deletion and duplication analysis can look for changes that standard testing may miss, and whole-exome or genome testing may also be appropriate depending on the clinical picture.
Why might parents have genetic testing after a child receives two DNAJC6 variants?
Parental testing can show whether the two variants are in trans, meaning one was inherited from each parent. This helps clarify the inheritance pattern, especially when the variants are different.

Get notified when new evidence is published on Juvenile onset Parkinson disease 19A.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.

References

References (7)
  1. 1

    DNAJC6 Mutations Disrupt Dopamine Homeostasis in Juvenile Parkinsonism-Dystonia.

    Ng J, Cortès-Saladelafont E, Abela L, et al.

    Movement disorders : official journal of the Movement Disorder Society 2020; (35(8)):1357-1368 doi:10.1002/mds.28063.

    PMID: 32472658
  2. 2

    Diagnosis of Primary Ciliary Dyskinesia by a Targeted Next-Generation Sequencing Panel: Molecular and Clinical Findings in Italian Patients.

    Boaretto F, Snijders D, Salvoro C, et al.

    The Journal of molecular diagnostics : JMD 2016; (18(6)):912-922 doi:10.1016/j.jmoldx.2016.07.002.

    PMID: 27637300
  3. 3

    DNAJC6 Mutations Associated With Early-Onset Parkinson's Disease.

    Olgiati S, Quadri M, Fang M, et al.

    Annals of neurology 2016; (79(2)):244-56 doi:10.1002/ana.24553.

    PMID: 26528954
  4. 4

    Whole-Exome Sequencing and Targeted Copy Number Analysis in Primary Ciliary Dyskinesia.

    Marshall CR, Scherer SW, Zariwala MA, et al.

    G3 (Bethesda, Md.) 2015; (5(8)):1775-81 doi:10.1534/g3.115.019851.

    PMID: 26139845
  5. 5

    Relationship of Genotype, Phenotype, and Treatment in Dopa-Responsive Dystonia: MDSGene Review.

    Weissbach A, Pauly MG, Herzog R, et al.

    Movement disorders : official journal of the Movement Disorder Society 2022; (37(2)):237-252 doi:10.1002/mds.28874.

    PMID: 34908184
  6. 6

    Childhood-onset parkinsonism, dystonia and severe muscle wasting in a Sudanese girl caused by a novel homozygous DnaJ heat shock protein family (heat shock protein 40) member C6 frameshift variant, with an incidental pathogenic breast cancer 1 gene secondary finding: a case report.

    Ahmed KAHM, Ahmed RKY

    Journal of medical case reports 2026; (20(1)).

    PMID: 42897672
  7. 7

    Hypotrichosis with juvenile macular dystrophy: Combination of whole-genome sequencing and genome-wide homozygosity mapping identifies a large deletion in CDH3 initially undetected by whole-exome sequencing-A lesson from next-generation sequencing.

    Saeidian AH, Vahidnezhad H, Youssefian L, et al.

    Molecular genetics & genomic medicine 2019; (7(11)):e975 doi:10.1002/mgg3.975.

    PMID: 31560841

This page is for informational purposes only and does not constitute medical advice. A neurologist or genetics professional should interpret your child's genetic report and guide decisions about additional testing.